SEC Filings
State Street Holds 4.4% Of Verastem In A Passive Position Measured In September
Verastem expects October financing and cancer-drug revenue to support operations into the first half of 2028.
Verastem (VSTM) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Verastem expects October financing and cancer-drug revenue to support operations into the first half of 2028.
SEC Filings
The company says cash plus expected product revenue should last into the first half of 2028, as it lays out 2026-2027 trial milestones.
Earnings
Verastem's development chief says regulators also allowed response rate as a dual primary endpoint, which could open an accelerated-approval route.
SEC Filings
The $8.00 price tops Tuesday's $7.45 last sale, and the new shares equal 25.5% of the count outstanding after the offering.
SEC Filings
The offering also includes pre-funded warrants for up to 312,503 shares and is expected to close on or about Thursday.
Earnings
The CEO handoff came with a first multi-tumor data update for VS-7375 and preliminary third-quarter product revenue of $23.9 million to $24.1 million.